PCSK9 and hyperlipidemia: In brief, these studies have shown that inhibition of PCSK9, a Federal Drug Administration-approved treatment for hyperlipidemia, reduces cardiovascular events, regulates inflammatory responses, and enhances the efficacy of immune checkpoint therapy in cancer treatment through a cholesterol-independent mechanism.